CompletedPhase 1

Dose-response Study of Exendin-9,39 on Glucose Metabolism

A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.

Lead sponsor

Adrian Vella

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01218633

Org study ID10-003435

Timeline

Milestones

Study first posted2010-10-11estimated

Last update posted2013-01-23estimated

Study start2011-05 (month precision)

Primary completion2012-07actual (month precision)

Study completion2012-12actual (month precision)

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age20 Years

Maximum age45 Years

SexAll

Healthy volunteersAccepted

Eligibility criteria

Healthy Not on any medication other than thyroid hormone replacement or OCP No history of diabetes No prior upper GI surgery

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.